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It is established that tumor cell-derived VEGF acts on
endothelial cells to promote angiogenesis and tumor
growth. Here, we demonstrate that in K5-SOS-
dependent mouse skin tumors, autocrine VEGF is
required for tumor cell proliferation in a cell-autono-
mous and angiogenesis-independent manner. VEGF
is upregulated in SOS-expressing tumors, and its
deletion in epidermal cells delays tumorigenesis by
suppressing angiogenesis and tumor cell prolifera-
tion. Epidermis-specific Flt1 deletion also impairs
tumorigenesis and proliferation. Surprisingly, com-
plete tumor inhibition occurs in the absence of
VEGF in EGFR mutant mice, demonstrating that
VEGFR and EGFR synergize in neoplastic cells to
promote tumor growth. Mechanistically, K5-SOS
upregulates VEGF, Flt1, and Neuropilin-1 in an Erk-
dependent manner, thereby activating an autocrine
proliferation loop, whereas EGFR prevents tumor
cells from apoptosis. Moreover, Flt1 is upregulated
in human SCC, and its inhibition in SCC cells impairs
proliferation. Thus, in addition to regulating angio-
genesis, VEGF has to be considered as a potent
growth factor for epidermal tumors.INTRODUCTION
The epidermal growth factor receptor (EGFR) family of receptor
tyrosine kinases includes ErbB1/EGFR, ErbB2/Neu, ErbB3, and
ErbB4 and is activated by ligand-dependent homo- or hetero-
dimerization (Schlessinger, 2002). Genetic ablation experi-
ments in mice revealed the importance of EGFR for the develop-
ment of different organs like brain, bone, heart, and several
epithelial tissues (Natarajan et al., 2007; Sibilia et al., 2007; Wag-
ner et al., 2006). EGFR overexpression and mutations have been268 Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc.detected at high frequency in tumors of epithelial and glial origin,
the same cell types also affected in mice lacking the EGFR
(Olayioye et al., 2000; Sibilia et al., 2007). We have shown that
transgenic mice expressing an activated form of the Ras acti-
vator Son of Sevenless from the keratin 5 promoter (K5-SOS
mice) develop spontaneous skin papillomas at 100% pene-
trance in a wild-type EGFR background. However, in a hypomor-
phic EGFRwa2/wa2 or null background, K5-SOS-dependent tumor
formation is severely impaired (Sibilia et al., 2000). In these mice,
the EGFR provides an essential survival signal to tumor cells by
activating the antiapoptotic Akt pathway, whereas SOS expres-
sion leads to increased proliferation by an unknown mechanism
(Sibilia et al., 2000).
Tumors and metastases usually arise as small avascular
masses that subsequently induce neovascularization in order
to acquire nutrients for continued growth and metastatic spread.
This angiogenic switch is induced by factors such as the
vascular endothelial growth factor (VEGF) secreted by tumor
cells (Bergers and Benjamin, 2003). VEGF is a key regulator of
vasculogenesis and angiogenesis and binds to two related
RTKs, VEGFR1/Flt1 and VEGFR2/KDR/Flk1, both of which are
primarily expressed on vascular endothelial cells (ECs), and to
neuropilins (Nrp), a family of coreceptors known to enhance
VEGFR signaling (Ferrara et al., 2003; Takahashi and Shibuya,
2005). Disruption of a single VEGF allele is embryonic lethal
because of abnormal vasculature. Similarly, Flt1/ and Flk1/
mice die in utero because of early defects in the development of
hematopoietic and endothelial cells (Ferrara et al., 2003, and
references therein). Conditional deletion of VEGF after birth in
various organs results in profound vascular anomalies and
lethality, whereas VEGF inactivation in older animals is much
less traumatic (Gerber et al., 1999). However, VEGF deletion in
the endothelial lineage leads to progressive endothelial degener-
ation and sudden death in mutant mice by 25 weeks of age, sug-
gesting that autocrine VEGF signaling is required for vascular
homeostasis (Lee et al., 2007a).
VEGF overexpression is found in many human and murine
tumors of epithelial origin and is linked to hypoxia and/or overex-
pression of various oncogenes, including mutant Ras and
Figure 1. Effect of Mutant EGFR and VEGF
Deletion on K5-SOS-Dependent Skin Tumor
Formation
(A) RNase protection assay showing mRNA
expression levels of VEGF and GAPDH in keratino-
cytes isolated from mice of the indicated geno-
types.
(B) Representative ELISA showing secreted VEGF
in supernatants of cultured keratinocytes. No
VEGF is detected in keratinocytes isolated from
VEGFflf K5-Cre (VEGFDep) mice.
(C) Tumor incidence in EGFRwa2/+ K5-SOS mice in
the presence or absence of VEGF.
(D) Tumor incidence in EGFRwa2/wa2 K5-SOS mice
lacking one or both VEGF alleles in the epidermis.
Only skin lesions R0.02 cm3 were scored as
tumors in all groups.
(E) Kinetic of tumor growth measured after ear
tip wounding of EGFRwa2/wa2 K5-SOS and
EGFRwa2/wa2 VEGFf/+ K5-Cre K5-SOS mice. No
tumors developed in EGFRwa2/wa2 VEGFDep
K5-SOS mice.
(F–H) Macroscopic appearance of ears 35 days
after wounding of EGFRwa2/wa2 K5-SOS (F),
EGFRwa2/wa2 VEGFf/+ K5-Cre K5-SOS (G), and
EGFRwa2/wa2 VEGFDep K5-SOS (H) mice.
(I) Average vessel area on aCD31-stained sections
from spontaneous papillomas from EGFRwa2/+ K5-
SOS andEGFRwa2/+ K5-SOSVEGFDep mice and of
wounding-induced tumors from EGFRwa2/wa2
K5-SOS and EGFRwa2/wa2 VEGFf/+ K5-Cre
K5-SOS mice.
(J) Quantification of Ki67+ cells on sections from
three independent tumors of mice indicated in (I).
Data represent mean ± SEM. *p % 0.05, **p %
0.005, ***p% 0.0005. See also Figure S1.activated EGFR (Bergers and Benjamin, 2003; Bergers and
Hanahan, 2008; Ferrara et al., 2003; Ferrara and Kerbel, 2005).
Interestingly, epidermis-specific VEGF deletion impaired
carcinogen-induced papilloma formation in mice (Rossiter
et al., 2004), and expression of dominant negative (dn) EGFR in
a Ras-dependent tumor model resulted in reduced VEGF
expression thereby leading to tumor angiogenesis and growth
suppression (Casanova et al., 2002). Recent reports demon-
strated expression of Flt1 and Flk1 as well as Nrp1 on tumor cells
(Chung et al., 2006; Fakhari et al., 2002; Lee et al., 2007b; Parikh
et al., 2004). Although in vitro it could be shown that VEGFR
signaling can mediate intracrine survival of tumor cell lines (Lee
et al., 2007b), the expression and function of VEGFRs in tumors
in vivo remains controversial.
By employing K5-SOS mice, we provide the first demonstra-
tion that VEGFR signaling is cell-autonomously required in skin
tumor cells to stimulate their proliferation in an autocrine and
angiogenesis-independent manner and that VEGFR and EGFR
signaling synergize in neoplastic cells to promote tumor growth.Cell 140, 268–279We show that epidermal tumor cells of
K5-SOS transgenic mice express high
levels of VEGF and its receptors Flt1
and Nrp1 in an Erk-dependent manner,and that genetic deletion of epidermal VEGF or Flt1 impairs
cancer cell proliferation, thereby resulting in reduced tumor
growth. Most importantly, Flt1 is upregulated in the majority of
human squamous cell carcinomas (SCC), a common skin
neoplasm frequently harboring activating Ras mutations,
thereby highlighting the relevance of the murine findings for
human epithelial tumor development.
RESULTS
Epidermal-Specific VEGF Deletion Delays K5-SOS-
Dependent Tumor Development
We found that K5-SOS expression significantly increased the
levels of VEGF messenger RNA (mRNA) and protein secretion
in both EGFRwa2/+ and EGFRwa2/wa2 keratinocytes (Figures 1A
and 1B). Moreover, VEGF levels were reduced by 40% in
EGFRwa2/wa2 and EGFR/ keratinocytes (Figures 1A and 1B),
demonstrating that EGFR and SOS positively control VEGF
expression. To investigate the effect of VEGF deletion during, January 22, 2010 ª2010 Elsevier Inc. 269
skin tumor development, we crossed K5-SOS mice of EGFR
wild-type and hypomorphic background with VEGFf/f mice
(Gerber et al., 1999) and further bred them with a K5-Cre trans-
genic line (Tarutani et al., 1997) to delete VEGF in the epidermis
(VEGFDep mice). Cre-mediated VEGF recombination was effi-
cient in epidermal cells and no mRNA and protein were detect-
able in keratinocytes (Figure 1B, and Figures S1A and S1B avail-
able online). In contrast, VEGF expression in skin ECs was not
affected (Figures S1C and S1D). Epidermis-specific VEGF dele-
tion significantly delayed the development and reduced the
average volume of tumors, which started to appear only after
1.5 months (Figure 1C and Figure S1F). These results indicate
that epidermal VEGF deletion significantly impairs K5-SOS-
dependent skin tumorigenesis.
No Tumor Development in the Absence of EGFR
and VEGF
K5-SOS-dependent tumor development is impaired in an
EGFRwa2/wa2 background and papillomas are always smaller
(Sibilia et al., 2000) (Figure 1D and Figure S1G). Interestingly,
when both VEGF alleles were deleted in an EGFRwa2/wa2 back-
ground, papilloma formation was completely inhibited (Fig-
ure 1D). Tumor incidence and the average tumor volume in the
absence of one VEGF allele were only slightly delayed (Figure 1D
and Figure S1G). Mechanical stress like wounding can induce
and accelerate tumor formation in EGFRwa2/wa2 K5-SOS
mice, and skin papillomas appear 2 weeks later (Figures 1E
and 1F). Therefore, small incisions were applied at the ear tip
of EGFRwa2/wa2 K5-SOS mice lacking one or both VEGF alleles.
In the presence of only oneVEGF allele, tumors were significantly
smaller after 35 days (Figures 1E and 1G). In contrast, no tumors
had developed in EGFRwa2/wa2 K5-SOS mice lacking both VEGF
alleles and these mice remained tumor free for more than
20 months (Figures 1E and 1H). These results demonstrate that
no tumors develop in the absence of EGFR and VEGF, suggest-
ing a synergistic effect of EGFR and VEGF signaling in tumor
development.
VEGF Deletion Dramatically Affects Tumor Cell
Proliferation and Blood Vessel Density
As previously described, papillomas of EGFRwa2/wa2 K5-SOS
mice were more differentiated, as evidenced by increased
numbers of keratin-1+ cells. This was not further affected by
the lack of VEGF (Figure S1H) (Sibilia et al., 2000). However,
the average vessel area and diameter was much lower in
EGFRwa2/+ VEGFDep K5-SOS tumors compared to the respective
controls. Deletion of only one VEGF allele did not affect vascular-
ization in EGFRwa2/wa2 K5-SOS tumors (Figure 1I and Figure S1I).
Interestingly, lack of VEGF not only reduced angiogenesis but
also dramatically decreased the number of proliferating tumor
cells (Figure 1J and Figure S1I). Five times less Ki67+ cells
were detectable in papillomas derived from EGFRwa2/+ VEGFDep
K5-SOS mice than in biopsies from controls. Furthermore, dele-
tion of one VEGF allele led to significantly reduced proliferation in
wounding-induced tumors of EGFRwa2/wa2 K5-SOS mice (Fig-
ure 1J). Epidermal proliferation was also significantly reduced
in healthy skin of EGFR wild-type and hypomorphic mice upon
VEGF deletion (Figure S1E). These data suggest that VEGF270 Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc.controls epidermal cell proliferation, which in combination with
reduced angiogenesis leads to the complete inhibition of tumor
formation in EGFRwa2/wa2 VEGFDep K5-SOS mice.
EGFR Signaling Is Required in Epidermal Cells to Induce
Tumor Formation
In EGFRwa2/wa2 mice, the EGFR is mutated in all cells, including
ECs. To investigate whether functional EGFR signaling is
required in a cell-autonomous manner in epidermal cells for
tumor induction, we employed conditional EGFR mice (EGFRf/f)
(Natarajan et al., 2007) to delete the EGFR exclusively in the
epidermis of VEGFf/f K5-SOS mice. The tamoxifen-inducible
K5-CreERT transgenic line (Indra et al., 1999) was employed
for EGFR (EGFRDepER) and VEGF (VEGFDepER) deletion in epi-
dermal cells at different stages of tumor development. Tamox-
ifen injection led to deletion of EGFR and VEGF in EGFRDepER
tumors and VEGFDepER keratinocytes, respectively (Figures
S2A and S2B). Ear tip wounding was employed to induce tumors
in mice of the indicated genotypes (Figure 2A, preventive trial).
While tumor onset occurred approximately 2 weeks later in all
five groups, the tumor volume was significantly reduced in
mice lacking epidermal VEGF both in an EGFRwa2/wa2 and
EGFRDepER background (Figure 2A). Interestingly, deletion of
only one VEGF allele in EGFRDepER mice was enough to severely
reduce tumor growth. This was not observed in an EGFRwa2/wa2
background, likely because the hypomorphic EGFR can still
signal, although at reduced levels compared to a wild-type
EGFR. These results demonstrate that the lack of EGFR expres-
sion in the epidermis is sufficient to inhibit K5-SOS-dependent
skin tumors in the absence of VEGF.
We next investigated whether VEGF and EGFR are also
required for tumor progression. After wounding-induced tumors
had developed, mice were treated with tamoxifen to delete
VEGF and/or EGFR (Figure 2B, therapeutic trial). While VEGF-
expressing tumors continued growing, deletion of VEGF in
EGFRwa2/wa2 K5-SOS tumors impaired their further growth and
their sizes remained unchanged throughout the entire treatment
period. Similar results were obtained if EGFR was deleted along
with VEGF (Figure 2B). These results show that VEGF and EGFR
are required both during tumor initiation and progression.
Combined Anti-VEGFR and Anti-EGFR Therapy Impairs
K5-SOS- and RasV12-Dependent Tumorigenesis
Anti-EGFR and anti-angiogenic therapies are being employed for
the treatment of several human cancers (Bergers and Hanahan,
2008; Ciardiello and Tortora, 2008; Ferrara, 2005). We next inves-
tigated whether pharmacological inhibition of EGFR and VEGF
signaling had a synergistic effect on inhibiting tumor growth.
A novel irreversible EGFR inhibitor (BI-2992) (Eskens et al.,
2008; Li et al., 2008; Riely, 2008) and a reversible VEGFR inhibitor
(BI-1120) (Hilberg et al., 2008), which are currently in phase III clin-
ical trials, were employed to treat tumor-bearing K5-SOS mice.
Whereas treatment with VEGFR inhibitor only mildly inhibited
tumor growth, EGFR inhibition significantly impaired tumor
growth, leading to tumor stasis for the remaining treatment
period (Figure 2C). Interestingly, combined therapy with both
inhibitors was even more effective and some tumors completely
regressed (Figure 2C). Importantly, when single EGFR inhibitor
Figure 2. Inducible Deletion of EGFR and
VEGF and Pharmacological Inhibition of
EGFR and VEGF Signaling in K5-SOS Trans-
genic Mice
(A) Kinetic of tumor growth measured in mice of
the indicated genotypes after ear tip wounding.
All mice had been treated with tamoxifen as indi-
cated in the scheme (prevention trial).
(B) Kinetic of tumor growth of established wound-
ing-induced tumors of the indicated genotypes
measured for 2 weeks. After tumors had devel-
oped, all mice were treated daily with tamoxifen
as indicated in the scheme (therapeutic trial).
(C) Relative tumor volume of K5-SOS mice treated
with vehicle (Natrosol), EGFR inhibitor (BI-2992),
VEGFR inhibitor (BI-1120), or combination therapy
with B-1120 and BI-2992. Arrows indicate the time
of termination of the respective treatment.
(D) Kinetic of RasV12-mediated tumor growth
upon treatment with the indicated inhibitors.
(E) Average vessel area on aCD31-stained tumor
sections of papillomas from mice treated with
the indicated inhibitors.
(F) Quantification of Ki67+ cells on sections from
three independent tumors of mice treated with
the indicated inhibitors.
Data represent mean ± SEM. *p % 0.05, **p %
0.005, ***p% 0.0005. See also Figure S2.treatment was stopped, tumor volumes increased very fast.
However, tumor regrowth was delayed in tumors treated with
both inhibitors, likely because neovascularization had to occur
(Figure 2C). Similarly to what was observed in the genetic exper-
iments, tumors treated with EGFR inhibitor were more differenti-
ated (Figure S2C). Interestingly, administration of EGFR or
VEGFR inhibitors resulted in a significantly lower blood vessel
density and dramatically decreased the number of proliferating
tumor cells (Figures 2E and 2F and Figure S2D). Furthermore,
EGFR inhibition increased apoptosis, which was enhanced by
additional treatment with VEGFR inhibitor (Figure S2D). These
results demonstrate that pharmacological inhibition of EGFR
and VEGFR signaling has a similar effect on tumor growth as
their respective genetic deletion.
To investigate whether EGFR and VEGF inhibitors are also
effective against Ras-dependent tumors, we induced subcuta-
neous tumors in nude mice with RasV12-transformed NIH 3T3
cells (Sibilia et al., 2000) and treated the resulting tumor-bearing
mice with the inhibitors. Similar to the results obtained with K5-
SOS mice, both inhibitors significantly impaired cancer develop-
ment (Figure 2D). Anti-EGFR therapy was more efficient than
anti-VEGFR treatment and the combination of both was most
effective (Figure 2D). Thus, anti-EGFR or anti-VEGFR therapies
alone or in combination can be efficiently employed to treat
Ras-dependent tumors.Cell 140, 268–279Molecular Analysis of Tumor Cells
Lacking EGFR and VEGF
To examine whether the absence of
tumors in K5-SOS mice lacking EGFR
and VEGF was due to a direct effect ofVEGF on tumor cells or an indirect mechanism mediated by
impaired angiogenesis, we analyzed primary keratinocytes iso-
lated from mice of various genotypes in vitro. Western blot anal-
ysis revealed that the levels of Erk1/2 phosphorylation were
always high in the presence of K5-SOS, irrespective of the
presence of the hypomorphic EGFR allele and/or the absence
of VEGF (Figure 3A). Erk phosphorylation was also increased
in SOS-expressing tumors regardless of the status of EGFR
and VEGF (Figure 3E). In contrast, activation of other MAP
kinases such as p38 and JNK was comparable among all geno-
types and not affected by K5-SOS expression (Figure 3A).
Phosphorylation of Akt was impaired in EGFRwa2/wa2 K5-SOS
keratinocytes (Sibilia et al., 2000) but not further affected by
additional deletion of VEGF (data not shown). Thus, SOS
expression leads to increased Erk1/2 activation both in vivo
and in vitro. Apoptosis was similar in keratinocytes of all geno-
types, and RNase protection assays revealed that expression
of various caspases was not affected by deletion of EGFR or
VEGF (data not shown). Several antiapoptotic genes were upre-
gulated in keratinocyte cultures when compared to epidermis,
and IL18, which is known to have an antiapoptotic effect on
keratinocytes, was highly induced in culture by K5-SOS (Fig-
ures S3A and S3B). These results might explain why EGFR
mutant keratinocytes in vitro do not display increased apop-
tosis as EGFR mutant epidermal cells in vivo (Sibilia et al.,, January 22, 2010 ª2010 Elsevier Inc. 271
Figure 3. VEGFR Expression and Prolifera-
tion in Epidermal Cells and Tumors
(A) Western blot analysis showing phosphorylation
of Erk1/2, p38, and JNK in protein lysates from
keratinocyte cultures isolated from mice of the
indicated genotypes.
(B) Quantification of BrdU+ cells in keratinocyte
cultures of the indicated genotypes.
(C and D) qRT-PCR measuring VEGFR1/Flt1 (C)
and Nrp1 (D) expression in cultured keratinocytes
of the indicated genotypes.
(E–G) Immunohistochemical analysis of phospho-
Erk1/2 (E), Nrp1 (F), and Flt1 (G) on sections of
spontaneous papillomas from EGFRwa2/+ K5-
SOS and EGFRwa2/+ K5-SOS VEGFDep mice and
of wounding-induced tumors from EGFRwa2/wa2
K5-SOS and EGFRwa2/wa2 VEGFf/+ K5-Cre
K5-SOS mice.
Note that Nrp1 expression is reduced in basal
tumor cells of EGFR mutant mice (B, black
arrows). Data in (B), (C), and (D) represent mean
± SEM. *p % 0.05, **p % 0.005, ***p % 0.0005.
See also Figure S3.2000). In accordance with the in vivo results, BrdU labeling
revealed that K5-SOS expression significantly increased the
proliferation of keratinocytes (Figure 3B). Interestingly, VEGF
deletion dramatically reduced the proliferation of EGFRwa2/+
as well as EGFRwa2/wa2 keratinocytes, even in the absence of
K5-SOS, whereas reduced EGFR signaling alone did not
affect proliferation (Figure 3B). If both EGFR and VEGF were
deleted, proliferation was even more reduced (Figure 3B).
These results demonstrate that VEGF deletion directly affects
proliferation of keratinocytes and SOS-transformed epidermal
tumor cells.
We next investigated whether VEGFRs were expressed in
epidermal cells and tumors. Interestingly, Flt1 and its corecep-
tor Nrp1 were expressed on keratinocytes, whereas Flk1 could
not be detected (Figures 3C and 3D and data not shown). While
Flt1 expression was not affected by reduced EGFR signaling,
Nrp1 levels were significantly lower in keratinocytes from272 Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc.EGFR mutant mice (Figures 3C and
3D). Interestingly, expression of both
Nrp1 and Flt1 was highly upregulated
by the K5-SOS transgene (Figures 3C
and 3D). However, K5-SOS-dependent
Nrp1 induction was slightly reduced in
EGFR mutant epidermal cells, suggest-
ing that Nrp1 expression is under the
control of EGFR signaling (Figures 3C
and 3D). Also K5-SOS tumors from
EGFR mutant mice expressed lower
levels of Nrp1 protein, whereas Flt1
levels were high in all K5-SOS tumors
(Figures 3F and 3G). These results
demonstrate that K5-SOS expression
leads to increased Erk activation and
upregulation of Flt1, Nrp1, and VEGFboth in vivo and in vitro resulting in increased VEGF-dependent
epidermal cell proliferation.
Autocrine VEGF-Flt1 Stimulation Controls Tumor Cell
Proliferation
Next, we examined whether VEGF mediates its effects by acti-
vating Flt1. Interestingly, the levels of Flt1 phosphorylation
were higher in keratinocytes expressing K5-SOS (Figure 4A).
Compared to wild-type cells, low levels of phosphorylated Flt1
could be detected already in starved K5-SOS keratinocytes,
suggesting that autocrine VEGF produced by these cells might
be responsible for this effect (Figure 4A). Furthermore, VEGF
stimulation induced Flt1 phosphorylation only in K5-SOS-
expressing cells (Figure 4A). Interestingly, stimulation with EGF
also led to Flt1 phosphorylation after 10 min and persisted for
4 hr, suggesting an autocrine mechanism mediated by VEGF
(Figure 4A). In K5-SOS-expressing epidermal cells, stimulation
Figure 4. VEGF Stimulation Induces
Epidermal Cell Proliferation by Activating
Flt1 and Erk
(A) Cultured keratinocytes were either left
untreated (bulk) or starved for 24 hr prior stimula-
tion with EGF or VEGF. Protein lysates were sub-
jected to immunoprecipitation (IP) with anti-Flt1
antibodies. Proteins were resolved by SDS-
PAGE and immunoblotted (IB) with the indicated
antibodies.
(B) Quantification of BrdU+ cells in keratinocyte
cultures of the indicated genotypes upon VEGF
treatment.
(C) Western blot analysis showing Erk phosphory-
lation in keratinocytes stimulated with EGF and
VEGF. Numbers indicate the levels of Erk1/2 acti-
vation relative to the respective controls after
correction with total Erk normalized to actin
(loading control).with VEGF also significantly induced Erk1/2 phosphorylation, as
well as cell proliferation (Figures 4B and 4C). In contrast, K5-SOS
negative keratinocytes expressing low levels of VEGFRs were
only poorly stimulated by VEGF (Figure 4C). These results
show that VEGF acts via stimulation of Flt1 and that the ability
of VEGF to stimulate downstream signaling pathways correlates
with the levels of VEGFR expressed on epidermal cells. To
further prove that autocrine VEGF-Flt1 signaling is responsible
for tumor cell proliferation, we knocked down both Flt1 and
Nrp1 in epidermal cells. Knockdown (KD) of either of them
resulted in a strong reduction in the number of proliferating cells,
further demonstrating that VEGF affects epidermal cell prolifera-
tion via these receptors (Figures 5A–5C). Moreover, epidermal
cells were also treated with the intracellular VEGFR kinase inhib-
itors Sunitinib (Potapova et al., 2006; Zhou et al., 2008) and
BI-1120 (Hilberg et al., 2008), and with the extracellular VEGFR
inhibitors aVEGFR1 (neutralizing antibody) and Flt2-11 (blocking
peptide) (Tan et al., 2001). All approaches revealed that cell
proliferation was decreased along with secretion of VEGF
(except for Flt2-11) and expression of Flt1 (except for Flt2-11)
and Nrp1 (Figures 5D–5G). This was associated with inhibition
of Erk activation (Figure S4A). The observation that the intracel-
lular inhibitors had a stronger effect than the extracellular sup-
pressors can be either due to the broader spectrum of inhibition
by Sunitinib and BI-1120 or to intracellular VEGFR activation,
which is not inhibited by the extracellular suppressors. Together,
our data suggest that autocrine epidermal cell proliferation via
Flt1 can occur intracellularly as well as via secreted VEGF.
To investigate whether the Erk1/2 pathway might control cell
proliferation via expression of VEGF and its receptors, we
treated keratinocytes with the MEK inhibitors CI-1040/PD-
184352 and UO126 (Bain et al., 2007; Liu et al., 2007; Lunghi
et al., 2008), which blocked Erk1/2 phosphorylation (Figures
S4B and S4C). Inhibition of Erk1/2 significantly affected keratino-
cyte proliferation, VEGF secretion, and VEGFR expression, even
when K5-SOS was expressed (Figures 5D–5G). These results
demonstrate that K5-SOS expression leads to constitutive acti-vation of Erk1/2, resulting in increased expression of VEGF and
its receptors, which in turn leads to increased tumor cell prolifer-
ation by strengthening the Erk pathway.
To further confirm that VEGF-mediated activation of Flt1 is
responsible for SOS-dependent tumor formation in vivo by
stimulating tumor cell proliferation, we crossed Flt1f/f mice
(Figure S4D) to K5-SOS and K5-Cre transgenic mice. Genomic
deletion of Flt1 (Flt1Dep) and absence of Flt1 expression in the
epidermis was confirmed by PCR and qRT-PCR, respectively
(Figures S4E and S4F). No Flt1 protein expression could be
detected in Flt1Dep K5-SOS tumors by immunohistochemical
staining (Figure S4I). In Flt1Dep K5-SOS mice, tumor growth
was significantly delayed, similar to what observed in K5-SOS-
expressing VEGFDep mice (Figures 5H–5J and 1C). Likewise,
epidermal tumor cell proliferation was also impaired (Figure 5K
and 1J), and Erk activation only moderately weaker than in the
respective controls (Figure S4H and Figure 3E). In contrast to
VEGFDep K5-SOS mice, blood vessel density was not affected
in Flt1Dep K5-SOS mice (Figure S4G and Figure 1I), which was
expected as K5-Cre deletes in epidermal cells, but not in ECs
(Figures S1C and S1D). These results definitively prove that the
VEGF/Flt1 signaling pathway controls epidermal cancer cell
proliferation in an angiogenesis-independent manner.
Human Epidermal Tumors and Cell Lines Express Flt1
and Its Coreceptor, Nrp1
To determine the relevance of these findings to human epidermal
cancer, we examined Flt1 and Nrp1 expression in human epi-
dermal tumors. Sections from 194 basal cell carcinoma (BCC)
and 163 squamous cell carcinoma (SCC) patients, as well as
95 normal skin samples, were analyzed by immunohistochem-
istry (Figures 6A–6E). In normal human skin, weak intracellular
Flt1 staining was observed in 40% of the samples, whereas
the remaining 60% did not show any Flt1 expression (Figures
6A and 6E). In BCC samples, the pattern of Flt1 expression
was similar to normal skin (Figure 6E). In contrast, 80% of SCC
samples expressed Flt1. Among the Flt1+ SCC samples, 21%Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc. 273
Figure 5. Inhibition of VEGFR and Erk
Affects Proliferation and Expression of
VEGF and Its Receptors
(A) Quantification of proliferating keratinocytes
after miRNA knockdown (KD) of Flt1 and Nrp1.
(B and C) Relative expression of Flt1 (B) and Nrp1
(C) upon KD with two different vectors.
(D) Quantification of proliferating keratinocytes
after treatment with VEGFR or Erk inhibitors.
Shown asterisks (*) refer to comparisons with
respective untreated controls. The following
p values were obtained in comparisons between:
EGFRwa/+: BI-1120 with aVEGFR, p = 0.01;
BI-1120 with Flt2-11, p = 0.02; Sunitinib with
aVEGFR, p = 0.04; EGFRwa2/+ K5-SOS: BI-1120
with aVEGFR, p = 0.02; BI-1120 with Flt2-11, p =
0.05; Sunitinib with aVEGFR, p = 0.02; Sunitinib
with Flt2-11, p = 0.05.
(E–G) Treatment with the inhibitors indicated in (D)
affects VEGF protein secretion after 48 hr (E) and
Flt1 (F) and Nrp1 (G) mRNA expression after
12 hr in cultured keratinocytes. Data represent
mean ± SEM. *p % 0.05. **p % 0.005. ***p %
0.0005.
(H) Tumor incidence in EGFRwa2/+ K5-SOS mice in
the presence or absence of Flt1. *** p % 0.0005.
Note that in this genetic background tumors
appear earlier and their progression is more
aggressive when compared to the tumor growth
kinetic in Figure 1C.
(I and J) Macroscopic appearance of spontaneous
tail tumors of EGFRwa2/+ Flt1Dep K5-SOS mice and
littermate controls at the age of 3 (I) and 4 weeks
(J). Asterisks indicate conditional Flt1 mutants of
two different litters.
(K) Quantification of Ki67+ cells in wounding-
induced tumors isolated from mice of the indi-
cated genotypes. Data represent mean ± SEM of
two independent samples. **p% 0.0005.
See also Figure S4.displayed strong cytoplasmic staining, and weak intracellular
expression was found in 60% of patient material (Figures 6D
and 6E). Overall, strong Flt1 staining at the cell membrane was
observed in 18% of SCC samples but only in 0.5% of BCC
patients, and normal skin was always negative (Figures 6C and
6E). Moreover, qRT-PCR analysis revealed that Flt1 expression
was increased in SCC biopsies compared to normal skin
(Figure S5A). Nrp1 expression was detectable in human normal
skin, BCC, and SCC, but its expression did not correlate with
the grade of malignancy (data not shown).
To address the functional relevance of Flt1 upregulation in
human SCC, we performed mechanistic studies in human SCC
cell lines. Out of six SCC lines, two expressed low levels and
four expressed high levels of Flt1 at the mRNA and protein level
(Figures S5B and S5C and data not shown). VEGF stimulation of
lines SCCO11 and SCC13, which displayed the highest level of
Flt1 expression, led to receptor phosphorylation (Figure S5C).
To examine whether autocrine VEGF-Flt1 signaling is respon-
sible for tumor cell proliferation also in human SCC, we knocked
down Flt1 in SCCO11 cells with short hairpin RNA (shRNA) lenti-274 Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc.viral vectors (Figure 6F and Figure S5C). Flt1 KD significantly
reduced the number of proliferating cells (Figure 6G). Further-
more, SCCO11 and SCC13 were treated with the intracellular
VEGFR kinase inhibitors Sunitinib and BI-1120 and the extracel-
lular VEGFR inhibitors aVEGFR1 and Flt2-11. Similar to what
observed with mouse epidermal cells, all compounds signifi-
cantly reduced cell proliferation in both SCC cell lines, except
for aVEGFR1 in SCCO11 (Figure 6H). Flt1 expression and activa-
tion was also inhibited by both intracellular VEGFR kinase inhib-
itors but not by the extracellular suppressors (Figure 6I and
Figure S5C). In contrast, Nrp1 expression was not affected
(Figure 6J), which correlates with the results in human SCC biop-
sies, where Nrp1 was expressed but its levels did not correlate
with the grade of malignancy. Also in human SCC, the effects
of the intracellular kinase inhibitors were stronger than the extra-
cellular suppressors, suggesting that autocrine intracellular
VEGFR signaling might contribute to the observed phenotypes.
Reduced Erk activation was also detectable after Flt1 KD and
treatment with VEGFR inhibitors (Figure S5D). In addition, similar
to what was observed with mouse tumor cells, treatment of the
Figure 6. Flt1 Is Upregulated in Human
Squamous Cell Carcinomas
(A–D) Immunohistochemical stainings with anti-
bodies against Flt1 (A, C, and D) and isotype con-
trol (B) showing Flt1 expression on human normal
epidermis (A) and SCC (C and D).
(E) Distribution of Flt1 protein expression on
human normal epidermis (epi), basal cell carci-
nomas (BCC), and SCC.
(F) Relative expression of Flt1 upon shRNA knock-
down (KD).
(G) Quantification of proliferating SCCO11 cells
after shRNA KD of Flt1.
(H) Quantification of proliferating SCC cells after
treatment with the indicated inhibitors. Shown
asterisks (*) refer to comparisons with respective
untreated controls. The following p values were
obtained in comparisons between: SCCO11:
BI-1120 with aVEGFR, p = 0.0197; BI-1120 with
Flt2-11, p = 0.0018; Sunitinib with aVEGFR, p =
0.0029; SCC13: BI-1120 with aVEGFR, p =
0.0037; BI-1120 with Flt2-11, p = 0.0015; Sunitinib
with aVEGFR, p = 0.0025; Sunitinib with Flt2-11,
p = 0.0004.
(I and J) Treatment with the indicated inhibitors
affects Flt1 and Nrp1 mRNA expression in SCC
cell lines after 24h.
Data represent mean ± SEM. *p % 0.05, **p %
0.005, ***p% 0.0005. See also Figure S5.SCC cell lines with the MEK inhibitors U0126 or CI-1040 impaired
Erk activation, resulting in significant reduction of proliferation
and Flt1 and Nrp1 expression (Figures 6H–6J and Figures S5E
and S5F), suggesting that in human cells, VEGFR expression
and cell proliferation are also controlled via the Erk pathway.
These results demonstrate that autocrine VEGF-Flt1 signaling
controls proliferation of human SCC cells and might therefore
be an attractive target for therapeutic intervention in SCC
patients.
DISCUSSION
It is accepted that VEGF produced by tumor cells acts on neigh-
boring VEGFR-expressing ECs to promote neovascularization
for continued tumor growth (Bergers and Benjamin, 2003; Fer-
rara et al., 2003; Ferrara and Kerbel, 2005). This concept has
been challenged by reports demonstrating expression of the
VEGFRs Flt1, Flk1, and Nrp1 on tumor cells (Bachelder et al.,
2001; Bielenberg et al., 2006; Chung et al., 2006; Gray et al.,
2005; Lee et al., 2007b; Parikh et al., 2004). We demonstrate
that in vivo autocrine VEGF is required for epithelial tumor cell
proliferation by activating Flt1 in a cell-autonomous and angio-
genesis-independent manner. Surprisingly, tumor development
was completely inhibited in the absence of epidermal VEGF
and EGFR expression, demonstrating a synergistic, tumor-
promoting effect of EGFR and VEGF signaling in neoplastic cells.
Similar results were also obtained with pharmacological EGFRand VEGFR inhibitors. It had previously been shown that expres-
sion of dn EGFR impaired Ras-dependent tumor growth by
affecting tumor vessels, which was likely due to reduced VEGF
expression (Casanova et al., 2002). However, we did not observe
reduced blood vessel density inK5-SOS tumors of mutant EGFR
background, and VEGF expression was comparable to controls,
suggesting that expression of activated SOS can overcome the
need for EGFR for efficient VEGF production. Only if VEGF
expression was absent in the epidermis the number of blood
vessels was significantly reduced in K5-SOS skin tumors.
The observation that inhibition of the VEGFR pathway in
K5-SOS mice results in strongly impaired tumor cell proliferation
could also be a consequence of reduced angiogenesis which
would prevent sufficient tumor nourishment. However, we
observed that proliferation was also reduced in vitro upon
genetic VEGF deletion or siRNA-mediated inhibition of Flt1 and
Nrp1, suggesting that VEGF has an additional cell-autonomous
effect on epidermal cells which is independent of angiogenesis.
Interestingly, genetic deletion of Flt1 in K5-SOS mice also signif-
icantly slowed down tumor growth and proliferation. However,
the reduction in proliferation observed in Flt1Dep K5-SOS tumors
was less than the one seen in VEGFDep K5-SOS tumors, sug-
gesting that VEGF deletion results in reduced K5-SOS-depen-
dent tumor burden not only by affecting tumor cell proliferation
but also by regressing tumor vessels.
Previous studies have shown that an intracellular autocrine
signaling loop for VEGF is required for the survival ofCell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc. 275
Figure 7. Autocrine VEGF Signaling Synergizes with EGFR in Tumor
Cells to Promote Epithelial Cancer Development
Model of K5-SOS/EGFR-mediated tumorigenesis via Erk-dependent upregu-
lation of Nrp1, Flt1, and VEGF expression, which leads to autocrine tumor cell
proliferation via the VEGF/Flt1 signaling pathway.hematopoietic stem cells and ECs (Gerber et al., 2002; Lee et al.,
2007a). We could show that Flt1 is expressed both intracellularly
and at the cell membrane in human SCC biopsies. This is likely
the same in K5-SOS tumor cells since the intracellular VEGFR
inhibitors had a stronger effect than the extracellular suppres-
sors. This can be due to either the broader spectrum of inhibition
by Sunitinib and BI-1120 or intracellular VEGFR activation, which
is not inhibited by the extracellular suppressors. Together,
our data suggest that autocrine Flt1 activation occurs intracellu-
larly as well as via VEGF secretion, leading to epidermal cell
proliferation.
Initially, VEGFRs were thought to be expressed only on ECs.
However, recent studies have suggested that these receptors
may also be expressed on tumor and epithelial cells (Bachelder
et al., 2001; Chung et al., 2006; Fan et al., 2005; Kim et al., 2005;
Kurschat et al., 2006; Lee et al., 2007b; Mercurio et al., 2004;
Parikh et al., 2004; Wilgus et al., 2005). Nrp1 expression was
reported on a variety of cancer cells, and its expression corre-
lates with poor prognosis (Bielenberg et al., 2006; Parikh et al.,
2004). However, there were also studies showing the opposite,
illustrating the complex function of Nrp1 in tumors (Gray et al.,
2005; Kamiya et al., 2006). We found that Nrp1 was expressed
in human BCC and SCC, but its expression did not correlate
with the grade of malignancy. In BCC samples, the pattern of
Flt1 expression was also similar to normal skin, but in most
SCC, Flt1 was upregulated with strong cytoplasmic expression.
In accordance with our finding, Lee et al. reported that Flt1 is
predominantly expressed intracellularly in breast cancer cell
lines and tumors and that VEGF is an internal autocrine survival
factor by binding to Flt1 (Lee et al., 2007b). Importantly, we could
show that various human SCC cell lines express increased levels
of Flt1, which is activated upon VEGF stimulation. Moreover, Flt1
KD in SCC cells or treatment with VEGFR inhibitors resulted in
a significant reduction of proliferation, whereby intracellular
inhibitors were more effective than extracellular suppressors.
Therefore, our data demonstrate that, similar to what observed
in mouse tumor cells, in human SCC, autocrine cell proliferation
controlled by Flt1 can also occur intracellularly, as well as by
VEGF secretion. Thus, VEGFR inhibitors might be attractive ther-
apeutics for different types of cancers.
In conclusion, we describe a new function for VEGF besides its
classical role as an angiogenic factor (Figure 7). We demonstrate
that in vivo, in a K5-SOS-dependent mouse skin tumor model,
autocrine VEGF is required for epithelial tumor cell proliferation
in a cell-autonomous manner. A similar mechanism occurs in
human SCC and might be utilized by human epithelial tumors
harboring oncogenic Ras signaling. In accordance to our data,
Mirones et al. showed that subcutaneous injection of Hras-trans-
duced keratinocyte cell lines lacking VEGF expression resulted
in smaller tumors with reduced tumor cell proliferation (Mirones
et al., 2009). However, they speculated that this effect was due
to reduced angiogenesis. We could show that K5-SOS expres-
sion leads to Erk-dependent upregulation of VEGF and its recep-
tors Flt1 and Nrp1 in tumor cells. Therefore, increased VEGF
induces tumor angiogenesis via a paracrine mechanism and
cell-autonomous tumor cell proliferation via an autocrine mech-
anism whereby Flt1 activation can occur intracellularly as well as
via VEGF secretion (Figure 7). Consequently, VEGF/VEGFR inhi-276 Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc.bition results in reduced K5-SOS-dependent tumor burden not
only by impairing angiogenesis but also by affecting tumor cell
proliferation. In K5-SOS mice also lacking EGFR, tumor cells
undergo apoptosis, and therefore papilloma formation is com-
pletely blocked (Figure 7). Similar results were also obtained
with therapeutics inhibiting EGFR and VEGFR. This study repre-
sents the first demonstration of a synergistic action of EGFR and
VEGF signaling in tumor cells and provides a molecular explana-
tion for why combined anti-EGFR and anti-VEGFR therapies
might be more efficient than single treatments.
EXPERIMENTAL PROCEDURES
Mice
VEGFf/f (Gerber et al., 1999), K5-SOS and EGFRwa2/wa2 (Sibilia et al., 2000),
EGFRf/f (Natarajan et al., 2007), K5-Cre (Tarutani et al., 1997), K5-CreERT
(Indra et al., 1999), and Flt1f/f (Ambati et al., 2006) mice were previously
described. For further information regarding Flt1f/f mice, please contact N.F.
For inducible VEGF and/or EGFR deletion, adult mice were injected intraperi-
toneally with 1 mg tamoxifen (Sigma; sunflower seed oil/ethanol mixture [10:1]
at 10 mg/ml) per day according to the schemes indicated in the figures. Mice
were kept in the animal facility of the Medical University of Vienna in accor-
dance with institutional policies and federal guidelines.
Pharmacological Inhibition of Tumor Growth
Inhibitors used in this study were kindly provided by Boehringer Ingelheim
Austria. Inhibitors were applied orally to K5-SOS mice at the following concen-
trations: BI-1120, 100 mg/kg/day; BI-2992, 20 mg/kg/day; and for combined
therapy, 75 mg/kg/day BI-1120 and 15 mg/kg/day BI-2992. The carrier Natro-
sol was given to untreated control mice. For induction of RasV12-dependent
tumor formation, athymic nu/nu mice were subcutaneously inoculated in the
flank area with 106 RasV12-transformed NIH 3T3 cells (Sibilia et al., 2000).
After tumors had developed, mice were treated with inhibitors as described
above.
Human SCC and Mouse Epidermal Cell Cultures, BrdU Staining,
and Inhibitor Treatment
Mouse epidermal cells were isolated as previously described and cultured on
vitrogen-fibronectin-coated dishes in low-calcium MEM medium (Sigma)
containing 8% chelated fetal calf serum (FCS) (Sibilia et al., 2000). The human
SCC cell lines SCC4 and SCC9 (ATCC) were kindly provided by Erwin
Tschachler, and SCCO11, SCCO12, SCC13, and SCCO22 by Gian-Paolo
Dotto, and they were cultured as previously described (Lefort et al., 2007).
Mouse or human cultures at 80% confluency were left untreated or stimulated
with 20 ng/ml EGF (Roche) or 30 ng/ml VEGF (R&D Systems) for 5 min and har-
vested for RNA or protein analysis. For VEGFR or Erk inhibition, 80% confluent
cells were treated with the VEGFR inhibitors Sunitinib (1 mM; Pfizer), BI-1120
(500 nM; Boehringer Ingelheim), anti-VEGFR1 antibody AF471 (2.5 mg/ml;
R&D Systems), VEGF blocking-peptide Flt2-11 (1 mg/ml; Calbiochem), and
the Erk inhibitors CI-1040 (500 nM; Pfizer), U0126 (10 mM; Promega), or
DMSO (Fluka) alone for 12–48 hr before supernatants, protein, or RNA lysates
were harvested for further analyses. For proliferation analysis of mouse kera-
tinocytes, 80% confluent cells were incubated with the respective inhibitors or
VEGF (100 ng/ml; R&D Systems) for 48 hr before pulsing with 10 mM BrdU
(Roche) for 4 hr, fixation with 70% ethanol, and immunofluorescent staining
with an anti-BrdU antibody according to the manufacturer’s instructions (Bec-
ton Dickinson). BrdU+ cells from six to ten randomly chosen fields of at least
three independent samples were counted. For proliferation analysis in human
SCC cell lines, 80% confluent cells were incubated with the respective inhib-
itors for 24 hr before pulsing with 20 mM BrdU (BD PharMingen) for 6 hr. Cells
were trypsinized and stained with the APC BrdU Flow Kit (BD PharMingen),
and the number of proliferating cells was analyzed on a LSR-II Flow cytometer
(BD Biosciences).
Knockdown of Flt1 and Nrp1 in Mouse Epidermal Cells
Four different miRNA oligos corresponding to Flt1 or Nrp1 and the nontarget
negative controls were purchased from Invitrogen and cloned into the
pcDNA6.2-GW/EmGFP-miR vector (Invitrogen) containing an EGFP marker
with the BLOCK-iT Pol II miR RNAi Expression Vector Kit according to the
manufacturer’s instructions. The vectors were transfected into primary
epidermal cells with Fugene HD (Roche). Twenty-four hours after transfection,
keratinocytes were pulsed with 20 mM BrdU for 6 hr. Transfection efficiencies
were measured by the expression of EmGFP by flow cytometric analysis and
ranged from 40% to 50%. For quantification of proliferation, cells were trypsi-
nized and stained with the APC BrdU Flow Kit (BD PharMingen). The
percentage of proliferating transfected (EGFP+/BrdU+) cells was analyzed
with a LSR-II flow cytometer (BD Biosciences) with FACSDiva software (BD
Biosciences). Proliferation rates were compared to the number of proliferating
cells transfected with the negative control vector. Expression of Flt1 or Nrp1
upon miRNA KD was quantified by qRT-PCR.
Knockdown of Flt1 in Human SCC
Human SCCO11 cells were transducted with three different SMARTvector
shRNA Lentiviral Particles targeting Flt1 or nontargeting control particles
(Dharmacon) according to the manufacturer’s instructions. For establishment
of cell lines that stably express the shRNA lentiviral constructs, cells were
cultured in medium containing 1 mg/ml puromycin. Only one out of three
constructs significantly knocked down Flt1 expression (qRT-PCR). Prolifera-
tion was quantified with the APC BrdU Flow Kit (BD PharMingen) as mentioned
above. Proliferation rates were compared to the number of proliferating cells
transducted with nontargeting control particles.
Isolation of Skin Endothelial Cells
Shaved dorsal and ventral skin was minced into pieces and incubated in colla-
genase (Wortington) for 60 min at 37C. The resulting cell suspension was
filtered and stained with antibodies against CD31, CD144 (BD Biosciences),
and CD45 (Coulter). Cellular suspensions were washed and CD31+ CD144+
CD45 ECs, CD31 CD144 CD45+ leukocytes, and CD31 CD144 CD45
stromal cells and keratinocytes were sorted to a purity of >95% on a FACSAria
Cell Sorter (BD Biosciences). Sorted cells were lysed in TRI Reagent (Sigma)
containing 1% b-mercaptoethanol (MERCK), and RNA was isolated according
to standard procedures.
Histological Analysis
Mouse tissues were embedded in OCT (Sakura), and 5 mm cryosections were
cut and fixed in acetone or 1% PFA before processing. Epidermal ear sheetswere prepared by separating epidermis from dermis with 3.5% ammonium-
thiocyanate and fixed in acetone. For immunohistochemistry and immunoflu-
orescent stainings, antibodies against the following antigens were used:
CD31/PECAM-1 (BD PharMingen); Ki67 (Novocastra); keratin 1 and keratin 14
(Babco); phospho-p44/42 (New England Biolabs); EGFR, Flt1, and Nrp1 (Santa
Cruz); and secondary antibodies purchased from Molecular Probes and Vector
Laboratories. For investigation of the average blood vessel density, a
computer-assisted morphometric analysis was performed with the MetaMorph
Imaging System. For antigen retrieval, paraffin-embedded human tissue
arrays were treated with Target Retrieval Solution (Dako) and processed further
according to the manufacturer’s recommendation. Isotype IgG from rabbit
serum (Sigma) and biotinylated anti-rabbit IgG (Vector Laboratories) were
used as controls.Southern Blot Analysis
Southern blot analysis was performed according to standard protocols.
Genomic DNA isolated from keratinocytes was digested with AccI. Floxed
and delta alleles of vegf were detected with a probe kindly provided by
J. Haigh.Total RNA Isolation, RT-PCR Analysis, and RNase Protection Assay
Total RNA from epidermis, cultured epidermal cells, SCC cell lines, or biopsies
were isolated with TRIzol Reagent (Invitrogen). RNase protection assays were
performed with the Multi-Probe RNase Protection Assay System (BD Biosci-
ences), and cDNA synthesis was performed with SuperScript First-Strand
Synthesis System (Invitrogen) according to the manufacturer’s instructions.
qRT-PCR was performed with the LightCycler FastStart DNA MasterPLUS
SYBR Green I kit together with the LightCycler 2.0 System (Roche). Primer
sequences are listed in Table S1.Western Blot Analysis and Immunoprecipitation
Cells were starved for 24 hr in 0.5% FCS or serum-free medium prior to growth
factor stimulation. Protein lysates were prepared as previously described
(Sibilia et al., 2000). For immunoprecipitation, 1.5 mg protein lysates were incu-
bated with anti-Flt1 antibodies precoupled to Ultralink immobilized Sepharose
beads (Pierce) according to the manufacturer’s recommendations and incu-
bated overnight at 4C. The bead-antibody-protein complexes were collected
by centrifugation, washed three times in lysis buffer, and resuspended in dena-
turing protein loading buffer. Proteins were separated by SDS-PAGE and
transferred to PVDF membranes (Millipore). Western blot analysis was per-
formed as previously described (Sibilia et al., 2000) with antibodies detecting
phospho-JNK, JNK, phospho-p38, p38 (Cell Signaling), phospho-p44/42
(New England Biolabs), Erk1/2 (Santa Cruz), phospho-tyrosine (Cell Signaling),
Flt1 (Abcam), actin, and tubulin (Sigma). Membranes were reprobed after strip-
ping in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM b-mercaptoethanol at
55C for 30 min.ELISA
Mouse VEGF Immunoassay (Quantikine, R&D Systems) was performed
according to the manufacturer’s instructions with 48 hr old supernatants
collected from 80% confluent keratinocyte cultures or with 40 mg protein of
epidermal cell lysates.Statistical Methods
All experiments were repeated at least twice and done in triplicate. Data were
evaluated with a Student’s two-tailed t test. p < 0.05 was taken to be statisti-
cally significant. In Figures 1C, 1D, and 5H data were analyzed by a log rank
(Mantel-Cox) test.SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and five figures and can be found
with this article online at doi:10.1016/j.cell.2009.12.046.Cell 140, 268–279, January 22, 2010 ª2010 Elsevier Inc. 277
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